Trials
36 active
52 in total · 35 in the EU
Targets
—
None known yet
What this is
- How it works
- TROP2-targeted antibody-drug conjugate
- How it’s given
- “Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.”In the company’s words, NCT04639986 on ClinicalTrials.gov
- Tested for
- Triple Negative Breast Cancer (4 trials), Non-Small Cell Lung Cancer (2 trials), Metastatic Breast Cancer (2 trials), Metastatic Triple-negative Breast Cancer (2 trials), Metastatic Urothelial Cancer (2 trials), Carcinoma, Non-Small-Cell Lung, PD-L1 Positive, Locally Advanced or Unresectable Metastatic Breast Cancer and 15 more
- Main trialPhase 3
- “The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).”In the company’s words, NCT05089734 on ClinicalTrials.gov
- Other names
- IMMU-132 · Trodelvy
Other drugs for Triple Negative Breast Cancer
- PembrolizumabMerck & Co. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- ESG401Qilu Pharmaceutical · Phase 3
- PumitamigBioNTech · Bristol Myers Squibb · Phase 3
Coming up12
- DecPhase 3 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- 12 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 1/2 trial completes · ClinicalTrials.gov
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- Sep 2028Phase 1 trial completes · ClinicalTrials.gov
- Jun 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials52
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 29 Nov 2023 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | |
| Phase 3Active, not recruiting | Dec 2026 | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | |
| Phase 3Active, not recruiting | 12 Jan 2027 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | |
| Phase 3Active, not recruiting | Feb 2027 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | |
| Phase 3Recruiting | Jun 2027 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | |
| Phase 3Active, not recruiting | Apr 2028 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | |
| Phase 3Active, not recruiting | Jul 2028 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | |
| Phase 3Active, not recruiting | Jun 2029 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | |
| Phase 3Recruiting | Oct 2029 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | |
| Phase 2Active, not recruiting | 6 Aug 2021 | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments | |
| Phase 2Active, not recruiting | 15 Jan 2025 | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | |
| Phase 2Active, not recruiting | 20 Jun 2025 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | |
| Phase 2Active, not recruiting | Oct 2026 | Study of Sacituzumab Govitecan in Patients With Solid Tumor | |
| Phase 2Active, not recruiting | Mar 2027 | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) | |
| Phase 2Active, not recruiting | Sep 2029 | Study of Novel Treatment Combinations in Patients With Lung Cancer | |
| Phase 2Active, not recruiting | Apr 2030 | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | |
| Phase 1/2Active, not recruiting | May 2027 | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors | |
| Phase 1/2Recruiting | Jun 2028 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | |
| Phase 1/2Recruiting | 30 Sep 2030 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | |
| Phase 1Recruiting | Dec 2026 | Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | |
| Phase 1Recruiting | Sep 2028 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | |
| Phase 4Completed | 18 Oct 2024 | Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | |
| Phase 3Completed | 30 Mar 2020 | Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | |
| Phase 3Completed | 20 Oct 2023 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | |
| Phase 3Completed | 4 Jul 2025 | Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | |
| Phase 2Withdrawn | Aug 2016 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | |
| Phase 2Terminated | 12 Jun 2024 | StrataPATH™ (Precision Indications for Approved Therapies) | |
| Phase 2Terminated | 8 Oct 2024 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer | |
| Phase 1/2Completed | 1 Mar 2019 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | |
| Phase 1/2Terminated | 8 Mar 2022 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | |
| Phase 1/2Completed | 30 Aug 2024 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | |
| Phase 1/2Terminated | 8 Oct 2025 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | |
| Phase 1Terminated | 16 Jun 2025 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | |
| Phase 3Authorised | not given | ISIdE: Open label, multicentric, single-arm phase IIIB trial to evaluate the safety and efficacy of sacituzumab govitecan in triple negative metastatic breast cancer patients with a biomarker analysis. | |
| Phase 2Authorised | not given | An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible for cisplatin-based chemotherapy. (PeRioperative Immunotherapy combined with Sacituzumab govitecan in Muscle invasive blAdder cancer) | |
| Phase 2Authorised | not given | A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP-2 antibody-drug conjugate sacituzumab govitecan in patients with advanced differentiated and anaplastic thyroid neoplasms. | |
| Phase 2Authorised | not given | Prospective biomarker analysis in HR+/HER2- advanced or metastatic breast cancer patients treated with sacituzumab govitecan (ACROSS-TROP2) | |
| Phase 2Authorised | not given | NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer (ADAPT-TN-III) | |
| Phase 3Authorised | not given | Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA | |
| Phase 3Authorised | not given | A phase III clinical trial of adjuvant treatment with Sacituzumab and Zimberelimab for stage IB-IIIA-IIIB (N2) previously resected (R0) non-small cell lung cancer (NSCLC) patients that did not achieve pathological complete response after neoadjuvant treatment (ARIAN) | |
| Phase 2Authorised | not given | Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study (COGNITION-GUIDE) | |
| Phase 2Ended | not given | Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative or Luminal Breast Cancer. – The PRIMED Study – | |
| Phase 2Authorised | not given | A single arm phase II study evaluating intracranial efficacy of Sacituzumab govitecan (SG) with bevacizumab in patients with asymptomatic brain metastases from non-small cell lung cancer (NSCLC) | |
| Phase 2Authorised | not given | SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy | |
| Phase 2Ended | not given | An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy | |
| Phase 3Authorised | not given | NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV) | |
| Phase 2Authorised | not given | Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystectomy patients: phase II trial (preSAVE trial) | |
| Phase 2Ended | not given | A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE) [without IMPD-Q] | |
| Phase 2Authorised | not given | A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin)- unresponsive non-muscle invasive bladder cancer (NMIBC) patients. | |
| Phase 2Authorised | not given | ABCSG 64 / neoGRACE: An open-label, two-arm, randomized phase II study of Sacituzumab Govitecan vs Standard of Care as neoadjuvant therapy for endocrine non-responsive ER+/HER2-negative early breast cancer | |
| Phase 2Ended | not given | A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study) | |
| Phase 2Authorised | not given | A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026